One player's minor pain is another's moderate gain. It's not often that a biotech wins when a big pharma stumbles, but Madrigal Pharmaceuticals (MDGL 0.64%) is now in a better place than before because of a setback at Danish drug giant Novo Nordisk (NVO 2.83%). The two cardiometabolic drug developers will avoid direct competition for the time being, and now, any head-tohead match up in the future could favor Madrigal a bit more than before. But is the biotech still a buy? Let's clarify the question by looki ...